1. Home
  2. BOX vs ACAD Comparison

BOX vs ACAD Comparison

Compare BOX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Box Inc.

BOX

Box Inc.

HOLD

Current Price

$28.66

Market Cap

3.6B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$26.22

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOX
ACAD
Founded
2005
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.8B
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
BOX
ACAD
Price
$28.66
$26.22
Analyst Decision
Buy
Buy
Analyst Count
8
22
Target Price
$35.57
$30.55
AVG Volume (30 Days)
2.2M
1.8M
Earning Date
05-26-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
0.08
0.02
Revenue
$506,142,000.00
$726,437,000.00
Revenue This Year
$9.41
$18.80
Revenue Next Year
$8.15
$11.70
P/E Ratio
$359.63
$1,320.00
Revenue Growth
26.98
40.45
52 Week Low
$21.34
$19.69
52 Week High
$33.88
$28.35

Technical Indicators

Market Signals
Indicator
BOX
ACAD
Relative Strength Index (RSI) 66.78 74.40
Support Level $23.52 $25.40
Resistance Level $28.80 $27.79
Average True Range (ATR) 0.95 0.94
MACD 0.29 0.23
Stochastic Oscillator 89.21 82.17

Price Performance

Historical Comparison
BOX
ACAD

About BOX Box Inc.

Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: